Literature DB >> 10485449

Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body.

T R Yeager1, A A Neumann, A Englezou, L I Huschtscha, J R Noble, R R Reddel.   

Abstract

Telomerase-negative immortalized human cells maintain their telomeres by a mechanism known as alternative lengthening of telomeres (ALT). We report here that ALT cells contain a novel promyelocytic leukemia (PML) body (ALT-associated PML body, APB). APBs are large donut-shaped nuclear structures containing PML protein, telomeric DNA, and the telomere binding proteins human telomere repeat binding factors 1 and 2. Immunostaining showed that APBs also contain replication factor A, RAD51, and RAD52, proteins involved in DNA synthesis and recombination. During immortalization, APBs appeared at exactly the same time as activation of ALT. APBs were found in ALT tumors and cell lines but not in mortal cell strains or in telomerase-positive cell lines or tumors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10485449

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  265 in total

1.  Activation of p53 protein by telomeric (TTAGGG)n repeats.

Authors:  M Milyavsky; A Mimran; S Senderovich; I Zurer; N Erez; I Shats; N Goldfinger; I Cohen; V Rotter
Journal:  Nucleic Acids Res       Date:  2001-12-15       Impact factor: 16.971

2.  An alternative lifestyle for immortalized oral keratinocytes.

Authors:  R R Reddel
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

3.  Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 cells.

Authors:  K Perrem; L M Colgin; A A Neumann; T R Yeager; R R Reddel
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

4.  Telomere repeat DNA forms a large non-covalent complex with unique cohesive properties which is dissociated by Werner syndrome DNA helicase in the presence of replication protein A.

Authors:  I Ohsugi; Y Tokutake; N Suzuki; T Ide; M Sugimoto; Y Furuichi
Journal:  Nucleic Acids Res       Date:  2000-09-15       Impact factor: 16.971

5.  Telomerase contributes to tumorigenesis by a telomere length-independent mechanism.

Authors:  Sheila A Stewart; William C Hahn; Benjamin F O'Connor; Elisa N Banner; Ante S Lundberg; Poonam Modha; Hana Mizuno; Mary W Brooks; Mark Fleming; Drazen B Zimonjic; Nicholas C Popescu; Robert A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-22       Impact factor: 11.205

6.  Telomerase extracurricular activities.

Authors:  Sandy Chang; Ronald A DePinho
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-23       Impact factor: 11.205

7.  p53 differentially inhibits cell growth depending on the mechanism of telomere maintenance.

Authors:  Zaineb R Abdul Razak; Robert J Varkonyi; Michelle Kulp-McEliece; Corrado Caslini; Joseph R Testa; Maureen E Murphy; Dominique Broccoli
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

8.  Rescue of an hTERT mutant defective in telomere elongation by fusion with hPot1.

Authors:  Blaine N Armbruster; Corinne M Linardic; Tim Veldman; Niharika P Bansal; Diane L Downie; Christopher M Counter
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

9.  Maintenance of very long telomeres by recombination in the Kluyveromyces lactis stn1-M1 mutant involves extreme telomeric turnover, telomeric circles, and concerted telomeric amplification.

Authors:  Jianing Xu; Michael J McEachern
Journal:  Mol Cell Biol       Date:  2012-05-29       Impact factor: 4.272

10.  Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma.

Authors:  Balakrishna Koneru; Gonzalo Lopez; Ahsan Farooqi; Karina L Conkrite; Thinh H Nguyen; Shawn J Macha; Apexa Modi; Jo Lynne Rokita; Eduardo Urias; Ashly Hindle; Heather Davidson; Kristyn Mccoy; Jonas Nance; Vanda Yazdani; Meredith S Irwin; Shengping Yang; David A Wheeler; John M Maris; Sharon J Diskin; C Patrick Reynolds
Journal:  Cancer Res       Date:  2020-04-14       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.